RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
20 nov. 2023 09h13 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
29 août 2023 08h00 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
28 juin 2023 22h55 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
31 mai 2023 09h05 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
29 mai 2023 20h57 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) is pleased to announce that it has closed its previously announced...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
01 mai 2023 22h44 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
20 avr. 2023 12h47 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
17 avr. 2023 18h18 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to announce that it has been invited to present at...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs
30 mars 2023 09h00 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of Red Cloud Securities (“Red Cloud”) and...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
22 mars 2023 09h00 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to...